Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Somaxon Pharmaceuticals Inc: Premium Company Profile Datamonitor, March 2008, Pages: 41   Description     Table of Contents        Enquire before Buying    Send to a Friend   Somaxon Pharmaceuticals (Somaxon) is a development stage pharmaceutical company engaged in in-licensing and developing proprietary product candidates for the treatment of psychiatry and neurology disorders. In January 2008, Somaxon submitted NDA with the FDA for Silenor for the treatment of insomnia. Scope - Contains corporate strategy, value chain presence and SWOT Analysis - Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors - Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights of this title Somaxon Pharmaceuticals enters into licensing agreements with pharmaceutical companies for developing therapeutics. In 2003, the company entered into licensing agreement with ProCom One for the exclusive, worldwide license to certain patents to develop and commercialize low dosages of Silenor for the treatment of insomnia. In the following year, BioTie Therapies granted the license of oral nalmefene hydrochloride to Somaxon. In addition, Somaxon received exclusive worldwide rights from Synchroneuron to certain patents to develop, manufacture and market acamprosate. During the forecast period 2006-2010, Somaxon is expected to derive its entire revenues from the launch of Silenor in 2009. Product sales of Silenor are expected to grow from $71 million in 2009 to $119 million in 2010. Key reasons to purchase this title - Access all the important information and analysis on the company in a single report - Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain - Gain access to companys adjusted five year financial data along with key ratios and market capitalization Customers who bought this item also bought Growth Strategies In Premium And Indulgent Food And Drinks To 2008: Increasing Profitability And Market Share Global Market Review of Premium Beer � Forecasts to 2013 The Growth of Premium Marketing Following the Leaders in Premium Fuel Retailing in Europe Developing Products With A Price Premium Premium Indulgence Premium Cards In Europe 2005 Skin Care in Taiwan

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster